PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
PETACH TIKVA, Israel, Oct.11, 2023 - PolyPid Ltd.(Nasdaq: PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, announced today that it has received a written notice from The Nasdaq Stock Market LLC (Nasdaq) confirming its regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2).This rule requires listed securities, including the Company’s ordinary shares, to maintain a minimum bid price of $1.00 per share.
As of the writing of this article, PolyPid Ltd’s share price stands at $3.89.This brings the year to date performance to -82.62%.This written notice from Nasdaq marks an important milestone for PolyPid Ltd, demonstrating their dedication to maintaining compliance with listing requirements.The minimum bid price is a significant factor for continued listing on the exchange, as it ensures a certain level of shareholder value and liquidity.
PolyPid Ltd is a late-stage biopharma company that specializes in the development of drug-Eluting Locally Administered Therapies (LAP) for surgical sites.Their innovative technologies aim to improve surgical outcomes and reduce complications such as infections.
This regained compliance with Nasdaq’s minimum bid price requirement serves as a vote of confidence for PolyPid’s vision and their ability to deliver on their promises.It reassures shareholders and potential investors that the Company is on track to achieve its strategic goals.
Throughout the year, PolyPid Ltd has faced challenges in the market, reflected in its year-to-date performance, which currently stands at -82.62%. However, it is important to note that the share price of $3.89 represents a significant increase from the minimum $1.00 threshold required by Nasdaq.This indicates an upwards trend in the Company’s market position.
PolyPid continues to make strides in the biopharmaceutical industry, leveraging its expertise in drug-Eluting Locally Administered Therapies.With regained compliance and an improved share price, PolyPid is well-positioned to attract more investors and continue its pursuit of improving surgical outcomes.
In conclusion, PolyPid Ltd’s recent announcement of regained compliance with Nasdaq’s minimum bid price requirement is a positive development for the Company.The share price standing at $3.89 reflects an upward trajectory and indicates increasing investor confidence.PolyPid’s dedication to improving surgical outcomes through innovative technologies positions them as a key player in the biopharmaceutical industry.
Comments